Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) EPS (Weighted Average and Diluted) (2016 - 2025)

Cytosorbents (CTSO) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.05 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) fell 25.0% year-over-year to -$0.05, compared with a TTM value of -$0.18 through Sep 2025, up 50.0%, and an annual FY2024 reading of -$0.38, up 41.54% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.05 for Q3 2025 at Cytosorbents, down from $0.03 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.03 in Q2 2025 and bottomed at -$0.28 in Q3 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.13, with a median of -$0.13 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 1331.96% in 2021, then surged 137.5% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.25 in 2021, then soared by 96.0% to -$0.01 in 2022, then crashed by 1200.0% to -$0.13 in 2023, then dropped by 7.69% to -$0.14 in 2024, then surged by 64.29% to -$0.05 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CTSO at -$0.05 in Q3 2025, $0.03 in Q2 2025, and -$0.02 in Q1 2025.